Nevirapine-associated rash with eosinophilia and systemic symptoms in a child with human immunodeficiency virus infection

Pediatric Infectious Disease Journal

Volumn 26, Issue 11, 2007, Pages 1053-1056

  Santos, Roberto P ^a,b   Ramilo, Octavio ^a,b   Barton, Theresa ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b CHILDREN S MEDICAL CENTER   (United States)

Author keywords

Adverse drug reactions; DRESS syndrome; Human immunodeficiency virus; Hypersensitivity syndrome; Nevirapine

Indexed keywords

ABACAVIR; DIDANOSINE; HLA DR ANTIGEN; IMMUNOGLOBULIN; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ANAMNESIS; ARTICLE; BLOOD CULTURE; CASE REPORT; CD4 LYMPHOCYTE COUNT; CHILD; CLINICAL FEATURE; DISEASE COURSE; DRESS SYNDROME; DRUG ERUPTION; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENETIC SUSCEPTIBILITY; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HLA TYPING; HOMOZYGOSITY; HOSPITAL ADMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; MEDICAL EXAMINATION; PATIENT MONITORING; PERINATAL INFECTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS LOAD; VIRUS RESISTANCE;

EID: 37349078609     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/INF.0b013e318125655d     Document Type: Article

References (19)

1. Bardsley-Elliot A, Perry CM. Nevirapine: a review of its use in the prevention and treatment of paediatric HIV infection. Paediatr Drugs. 2000;2:373-407.
2. Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin Cutan Med Surg. 1996;15:250-257.
3. Bourezane Y, Salard D, Hoen B, Vandel S, Drobacheff C, Laurent R. DRESS (drug rash with eosinophilia and systemic symptoms) syndrome associated with nevirapine therapy. Clin Infect Dis. 1998;27:1321-1322.
4. Lanzafame M, Rovere P, De Checchi G, Trevenzoli M, Turazzini M, Parrinello A. Hypersensitivity syndrome (DRESS) and meningoencephalitis associated with nevirapine therapy. Scand J Infect Dis. 2001;33:475-476.
5. Claudio GA, Martin AF, de Dios Perrino S, Velasco AA. DRESS syndrome associated with nevirapine therapy. Arch Intern Med. 2001;161:2501-2502.
6. Fields KS, Petersen MJ, Chiao E, Tristani-Firouzi P. Case reports: treatment of nevirapine-associated dress syndrome with intravenous immune globulin (IVIG). J Drugs Dermatol. 2005;4:510-513.
7. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356:1255-1259.
8. Martin AM, Nolan D, James I, et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS. 2005;19:97-99.
9. Yang J, Qiao HL, Zhang YW, Jia LJ, Tian X, Gao N. HLA-DRB genotype and specific IgE responses in patients with allergies to penicillins. Chin Med J (Engl). 2006;119:458-466.
10. Kim SH, Park HS. Genetic markers for differentiating aspirin- hypersensitivity. Yonsei Med J. 2006;47:15-21.
11. Clay PG. The abacavir hypersensitivity reaction: a review. Clin Ther. 2002;24:1502-1514.
12. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-245.
13. Pitche P, Drobacheff-Thiebaut C, Gavignet B, Mercier M, Laurent R. [Cutaneous drug-reactions to nevirapine: study of risk factors in 101 HIV-infected patients]. Ann Dermatol Venereol. 2005;132(12 pt 1):970-974.
14. Dieterich DT, Robinson PA, Love J, Stern JO. Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. Clin Infect Dis. 2004;38(suppl 2):S80-S89.
15. Bossi P, Colin D, Bricaire F, Caumes E. Hypersensitivity syndrome associated with efavirenz therapy. Clin Infect Dis. 2000;30:227-228.
16. Tancrede-Bohin E, Grange F, Bournerias I, Roujeau JC, Guillaume JC. Hypersensitivity syndrome associated with zalcitabine therapy. Lancet. 1996;347:971.
17. Sissoko D, Ajana F, de la Tribonniere X, Baclet V, Mouton Y. [Cutaneous, hepatic and hematologic manifestations due to nevirapine: DRESS syndrome? ]. Presse Med. 2000;29:1041-1042.
18. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998;282:490-493.
19. Claes P, Wintzen M, Allard S, Simons P, De Coninck A, Lacor P. Nevirapine-induced toxic epidermal necrolysis and toxic hepatitis treated successfully with a combination of intravenous immunoglobulins and N-acetylcysteine. Eur J Intern Med. 2004;15:255-258.